What Is Zofran?
Zofran, also trademarked Ondansetron, is a doctor prescribed drug that blocks the chemical bodily actions that can cause nausea and vomiting. The drug is meant to be used to prevent nausea and vomiting that might come about via surgery or cancer treatments. Zofran was initially approved for this very specific use of suppressing nausea and vomiting in cancer and post-operative patients by the Food and Drug Administration (FDA) in 1991.
Fast forward to 2011, the FDA issued a statement saying they were investigating the drug because they had plausible concern that the there was a link between the drug and heart defects. Prior to the FDA’s statement regarding the potential risk of taking the drug, there had been studies that pointed to the possibility of child birth defects if Zofran was ingested by an expectant mother. These studies came about due to Zofran being marketed as a drug that can be used to relieve pregnant women of Hyperemesis gravidarum (HG). Hyperemesis gravidarum is the medical term for what is commonly referred to as severe morning sickness.
The FDA never approved of Ondansetron for use in pregnant women suffering from extreme cases of morning sickness.
Connecticut Related Birth Abnormalities
It is estimated that one in 33 babies is born in the United States is born with some kind of birth abnormality. As of the latest census data, Connecticut’s population rests at 3,596,677. Connecticut’s five densely populated cities have the following totals:
- Bridgeport- 147,612 population
- New Haven- 130,282 population
- Stamford- 128,278 population
- Hartford- 124,705 population
- Waterbury- 109,307 population
Using that number of Connecticut residents, our Zofran attorneys have gauged the possible number of birth defects caused by Zofran in that state to be 2,186-based on the studies that determine certain types of defects developing, the total number of Connecticut residents and birth rates in the state.
Orofacial Cleft & CHDs Data In Connecticut & Its Populous Cities
With Connecticut’s population at 3,596,677 we further gauged that 736 births were some type of orofacial cleft and 1,450 were some type of what is broadly referred to as congenital heart defects (hole in the heart) brought on by the usage of Zofran in the first twelve weeks of gestation. A city by city breakdown of the five biggest cities in Connecticut yielded the results below:
- Bridgeport- 120 total birth defects with a ratio of 15 orofacial cleft, and 105 CHDs
- New Haven- 111 total birth defects with a ratio of 11 orofacial cleft and 100 CHDs
- Stamford- 110 total birth defects with a ratio of 12 orofacial cleft, and 98 CHDs
- Hartford- 108 total birth defects with a ratio of 11 orofacial cleft, and 97 CHDs
- Waterbury- 101 total birth defects with a ratio of 10 orofacial cleft, and 91 CHDs
Recorded Secondary Effects Of Taking Zofran
We mentioned already that there have been various medical studies carried out that have witnessed a link between Zofran and a heightened chance of a baby being born with abnormalities like hole in the heart, cleft palate and more. GlaxoSmithKline has never conducted tests to see if Zofran has any secondary effects on unborn babies exposed to this drug in utero. But, filed lawsuits against the company cite Zofran as the cause of the following secondary effects in their children:
- Congenital anomalies of the kidney
- Low set ears
- Bicuspid aortic stenosis
- Supraventricular tachycardia
- Facial Dysmorphia
- Cleft Palate
In 2012 an American medical study found a 2.37 times increased probability of a baby being born with a cleft palate when a mother used Zofran for morning sickness in the first 12 weeks of the baby’s development against a mom who did not use the drug at all. Click here for more details about this particular study.
Connecticut Parents Looking To File A Zofran Lawsuit
Zofranlegal.com, was funded and developed by the law firms of Monheit Law, Janet Jenner & Suggs, Grant Eisenhofer, Markhoff & Mittman, and Banville Law, in an effort to supply up to the minute news about Zofran lawsuits.
Although our attorneys are not certified to practice law in the state of Connecticut, we are certified in the state of Delaware and hold offices there too. Delaware State is also where the manufacturers of Zofran house their headquarters. The benefits of our Delaware offices are that we can directly work on your case if it is filed in the state of Delaware. Meet our Delaware team here.
Another option we offer is either filing your lawsuit in Delaware or another suitable location, or we can make recommendations on your behalf for local Connecticut legal representation to represent your case.
Please call us for more information. We are here to discuss the details of your case at any time. To learn more about our Zofran advocates click here.